Table 5.

Effect of >10 novel surface HLA-DRB1–tFVIII peptide binding combinations on inhibitor risk

OR (95% CI)
Unadjusted model 4.4 (1.4-14.0) 
Adjusted model* 4.1 (1.1-15.0) 
OR (95% CI)
Unadjusted model 4.4 (1.4-14.0) 
Adjusted model* 4.1 (1.1-15.0) 
*

Adjusted for intensive FVIII treatment.

Likelihood Ratio Test for interaction between >10 novel peptides and intensive FVIII treatment indicated no statistically significant interaction, P = .6.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal